Efficacy of bevacizumab maintenance therapy in advanced ovarian cancer

Qing Han, Aiqin He, Haibo Xu, Can Zhang, Yunfen Qiu, Yong Li

Abstract

This study aimed to evaluate the efficacy of bevacizumab maintenance therapy in advanced ovarian cancer and its impact on the Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3)/vascular endothelial growth factor A (VEGFA) pathway. A total of 126 patients were enrolled, divided into two groups: control (n=62) and study (n=64). The control group received neoadjuvant chemotherapy, tumor debulking surgery, and postoperative adjuvant chemotherapy. The research group received postoperative bevacizumab maintenance therapy in addition to standard treatment. Results showed that the research group had significantly improved disease control rates (43.75% vs. 24.19%, P=0.0206), objective response rates (76.56% vs. 48.39%, P=0.0011), overall survival (30.45±7.69 months vs. 22.92±7.26 months, P<0.0001) and progression-free survival (16.08±2.46 months vs. 12.08±2.25 months) compared to controls. Bevacizumab also led to lower levels of Janus kinase 2 (JAK2), signal transducer and activator of transcription 3 (STAT3) and vascular endothelial growth factor A (VEGFA) expression. This therapy demonstrated safety and efficacy, significantly prolonging progression-free survival and overall survival.

Full Text:

PDF

References

Zhang H, Wang L and Wu H. Liquid biopsy in ovarian cancer

in China and the world: current status and future

perspectives[J].

Front

;13:1276085.

Oncol.

Dec

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram

I, Jemal A and Bray F. Global Cancer Statistics 2020:

GLOBOCAN Estimates of Incidence and Mortality

Worldwide for 36 Cancers in 185 Countries[J]. CA

Cancer J Clin. 2021 May;71(3):209-249.

Oliveira LRLB, Horvat N, Andrieu PIC, Panizza PSB, Cerri

GG and Viana PCC. Ovarian cancer staging: What the

surgeon needs to know[J]. Br J Radiol. 2021 Sep

;94(1125):20210091.

Ferrari P, Scatena C, Ghilli M, Bargagna I, Lorenzini G and

Nicolini A. Molecular Mechanisms, Biomarkers and

Emerging Therapies for Chemotherapy Resistant

TNBC[J]. Int J Mol Sci. 2022 Jan 31;23(3):1665.

Wang Z, Li J, Guo J and Wei P. Direct antitumor activity of

bevacizumab: an overlooked mechanism[J]? Front

Pharmacol. 2024 Apr 23;15:1394878.

Chou HH, Chen WC, Yang LY, Huang HJ, Chang WY, Lin

H, Wu RC, Chen MY, Qiu JT, Huang KG, Chao A,

Chang TC and Lai CH. Postoperative adjuvant dose

dense chemotherapy with bevacizumab and

maintenance

bevacizumab

after

neoadjuvant

chemotherapy for advanced ovarian cancer: A phase

II

AGOG/TGOG trial[J]. Eur J Obstet Gynecol

Reprod Biol. 2021 Jul;262:13-20.

Zhao Y, Wang J, Liu WN, Fong SY, Shuen TWH, Liu M,

Harden S, Tan SY, Cheng JY, Tan WWS, Chan JKY,

Chee CE, Lee GH, Toh HC, Lim SG, Wan Y and Chen

Q. Analysis and Validation of Human Targets and

Treatments Using a Hepatocellular Carcinoma

Immune Humanized Mouse Model[J]. Hepatology.

Sep;74(3):1395-1410.

Xu F, Ye Y, Gao Y and Xu S. Dual Role of Necroptosis in

Cervical Cancer: Promoting Tumor Aggression and

Modulating the Immune Microenvironment via the

JAK2-STAT3 Pathway[J]. J Cancer. 2024 Aug

;15(16):5288-5307.

Miceli V, Gennarini M, Tomao F, Cupertino A, Lombardo D,

Palaia I, Curti F, Riccardi S, Ninkova R, Maccioni F,

Ricci P, Catalano C, Rizzo SMR and Manganaro L.

Imaging of Peritoneal Carcinomatosis in Advanced

Ovarian Cancer: CT, MRI, Radiomic Features and

Resectability Criteria[J]. Cancers (Basel). 2023 Dec

;15(24):5827.

Azaïs H, Koual M, Bentivegna E and Bats AS. Ovarian

cancer surgery [Chirurgie des cancers de l'ovaire][J].

Rev Prat. 2022 Jun;72(6):627-631. French.

Ngu SF, Ngan HY and Chan KK. Role of adjuvant and post

surgical treatment in gynaecological cancer[J]. Best

Pract Res Clin Obstet Gynaecol. 2022 Jan;78:2-13.

Mikkelsen MS, Petersen LK, Blaakaer J, Marinovskij E,

Rosenkilde M, Andersen G, Bouchelouche K and

Iversen LH. Assessment of peritoneal metastases with

DW-MRI, CT, and FDG PET/CT before

cytoreductive surgery for advanced stage epithelial

ovarian cancer[J]. Eur J Surg Oncol. 2021

Aug;47(8):2134-2141.

Ben Aziz M and Di Napoli R. Hyperthermic Intraperitoneal

Chemotherapy[J]. 2023 Jul 31. In: StatPearls

[Internet]. Treasure Publishing; 2024 Jan–. Island (FL): StatPearls

Lin CN, Liang YL, Tsai HF, Wu PY, Huang LY, Lin YH,

Kang CY, Yao CL, Shen MR and Hsu KF. Adipocyte

pyroptosis occurs microenvironment in and omental is associated tumor with

chemoresistance of ovarian cancer[J]. J Biomed Sci.

Jun 11;31(1):62.

De Blasis I, Moruzzi MC, Moro F, Mascilini F, Cianci S,

Gueli Alletti S, Turco LC, Garganese G, Scambia G

and Testa AC. Role of ultrasound in advanced peritoneal malignancies[J]. Minerva Med. 2019

Aug;110(4):292-300.

Chung SK, Vargas DB, Chandler CS, Katugampola S,

Veach DR, McDevitt MR, Seo SH, Vaughn BA,

Rinne SS, Punzalan B, Patel M, Xu H, Guo HF,

Zanzonico PB, Monette S, Yang G, Ouerfelli O, Nash

GM, Cercek A, Fung EK, Howell RW, Larson SM,

Cheal SM and Cheung NV. Efficacy of HER2

Targeted Intraperitoneal 225Ac α-Pretargeted

Radioimmunotherapy for Small-Volume Ovarian

Peritoneal Carcinomatosis[J]. J Nucl Med. 2023

Sep;64(9):1439-1445.

Zhou X, Liu M, Sun L, Cao Y, Tan S, Luo G, Liu T, Yao Y,

Xiao W, Wan Z and Tang J. Circulating small

extracellular vesicles microRNAs plus CA-125 for

treatment stratification in advanced ovarian cancer[J].

J Transl Med. 2023 Dec 22;21(1):927.

Fagotti A, Ferrandina MG, Vizzielli G, Pasciuto T, Fanfani

F, Gallotta V, Margariti PA, Chiantera V, Costantini

B, Gueli Alletti S, Cosentino F and Scambia G.

Randomized trial of primary debulking surgery versus

neoadjuvant chemotherapy for advanced epithelial

ovarian cancer (SCORPION-NCT01461850)[J]. Int J

Gynecol Cancer. 2020 Nov;30(11):1657-1664.

Chen KB, Wu ZW, Huang Y, Kang MX, Lin LL, Jiang SS,

Zhang H, Huang YJ and Chen L. Successful outcome

of neoadjuvant PD-1 blockade, VEGFR-2 inhibitor

plus chemotherapy for potentially unresectable

esophagogastric junctional squamous cell carcinoma:

a case report[J]. Transl Cancer Res. 2022

Sep;11(9):3329-3336.

Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL,

Deurloo R and Chinot OL. Bevacizumab (Avastin®)

in cancer treatment: A review of 15 years of clinical

experience and future outlook[J]. Cancer Treat Rev.

Jun;86:102017.

Mengie Ayele T, Tilahun Muche Z, Behaile Teklemariam A,

Bogale Kassie A and Chekol Abebe E. Role of

JAK2/STAT3 Signaling Pathway in the

Tumorigenesis, Chemotherapy Resistance, and

Treatment of Solid Tumors: A Systemic Review[J]. J

Inflamm Res. 2022 Feb 25;15:1349-1364.

Shen X, Wang D, Chen X and Peng J. Propofol inhibits

proliferation, migration, invasion and promotes

apoptosis

by regulating HOST2/JAK2/STAT3

signaling pathway in ovarian cancer cells[J].

Cytotechnology. 2021 Apr;73(2):243-252.

Long L, Fei X, Chen L, Yao L and Lei X. Potential

therapeutic targets of the JAK2/STAT3 signaling

pathway in triple-negative breast cancer[J]. Front

Oncol. 2024 Apr 18;14:1381251.

Pei CZ, Seok J, Kim GJ, Choi BC and Baek KH. Deficiency

of HtrA4 in BeWo cells downregulates angiogenesis

through IL-6/JAK/STAT3 signaling[J]. Biomed

Pharmacother. 2023 Oct;166:115288.

Sun M, Jiang W. Ovarian clear cell carcinoma with or

without endometriosis origin in a single institution

cohort[J]. Discov Oncol. 2023 Apr 1;14(1):39.

Cheng CY, Hsu HC, Tai YJ, Chiang YC, Chen YL and

Cheng WF. Outcome and prognostic factors of

unexpected ovarian carcinomas[J]. Cancer Med. 2023

Mar;12(6):6466-6476

Refbacks

  • There are currently no refbacks.